Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus

Alexandros P. Grammatikos and George C. Tsokos

Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Recent evidence suggests that systemic autoimmunity and immunodeficiency are not separate entities, but rather are interconnected processes. Immunodeficiency results from distinct defects of the immune response and primarily presents as infections but also frequently with autoimmune features. Systemic autoimmunity is the combined effect of multiple genetic variations and infectious and immunoregulatory factors that result in dominant autoimmune manifestations, in addition to frequent and opportunistic infections. The overlap in disease manifestations and symptoms suggests that immunodeficiency should be considered in the presence of autoimmunity, and *vice versa*. In this review, we present the shared or similar aspects of immunodeficiency and autoimmunity using systemic lupus erythematosus as a paradigm and discuss the implications for clinical care.

The basis of systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an immune complex disease that predominantly affects women of reproductive age. Multiple autoantibodies are produced that bind diverse nuclear antigens, including double-stranded DNA, RNP (ribonucleoproteins) and Sm (Smith). These autoantibodies deposit on several organs, including kidneys, skin and joints, causing inflammation [1]. The etiology of SLE has still not been clearly elucidated, but a strong genetic contribution to disease development is postulated to exist. Gene polymorphisms, single nucleotide polymorphisms (SNPs), gene deficiencies and duplications, and aberrant expression of splice variants have all been identified as contributing to the expression of SLE in certain individuals [2]. Genome-wide association studies (GWAS) performed in SLE patients have identified intriguing links between genetic diversity in major components of the immune system and susceptibility to SLE [3]. What is even more interesting is that genetic variations in genes previously associated with immunodeficiency are now also linked to SLE [4,5]. Complete understanding of gene involvement in the expression of the disease may improve our understanding of the pathways used by pathogens and other environmental contributors to disease pathology [6,7].

Several cases in which monogenic defects in genes encoding immune system components lead to immunodeficiency

and a phenotype associated with infections by specific microbial agents have recently been reported [6]. Examples are patients with late complement component deficiencies who are particularly prone to infection with *Neisseria*

Glossary

Adrenocortical failure: insufficiency of the cortical part of the adrenal gland, which is responsible for the production of corticosteroids, aldosterone and androgenic steroids. This can be caused by many factors, including infections, emboli, and tumors.

Agammaglobulinemia (or hypogammaglobulinemia): absence, or very low levels, of immunoglobulins (antibodies), resulting in the development of multiple infections.

Atopy: inherited predisposition that causes a tendency to suffer from one or more allergic diseases, such as asthma, rhino-conjunctivitis and dermatitis.

Autoimmune thrombocytopenia: a disorder involving low blood platelet count in which platelets are destroyed by antibodies produced by the immune system.

CD4+ T helper cells: are cells responsible for orchestrating the immune response and providing signals for the activation of other immune cells, such as B and cytotoxic T lymphocytes.

Chronic mucocutaneous candidiasis: a group of disorders characterized by recurrent or persistent infections of the skin, mucous membranes, and nails with *Candida* organisms.

Granuloma: a mass or nodule of inflamed tissue characterized histologically by transformed macrophages (epithelioid cells) surrounded by lymphocytes.

Granulomatosis with polyangiitis (Wegener's): a vasculitic disorder characterized by inflammation (vasculitis) of small and medium blood vessels and the presence of granulomas, mainly in sinuses, lungs, and kidneys.

Hemophagocytic lymphohistiocytosis (HLH): a syndrome characterized by fever, hepatosplenomegaly, and lymphadenopathy due to uncontrolled cytotoxic T cell activation and tissue infiltration with histiocytes (macrophages).

Hepatosplenomegaly: simultaneous enlargement of both the liver and spleen.

Hypergammaglobulinemia: presence of elevated levels of immunoglobulins (belonging to the gamma globulin fraction in serum electrophoresis) in blood serum. Can be polyclonal (multi-epitope-specific, as seen in chronic inflammatory conditions) or monoclonal (specificity for a single epitope).

Hypoparathyroidism: a disease characterized by decreased function of the parathyroid glands, responsible for the production of parathyroid hormone and body calcium homeostasis.

Lymphadenopathy: enlargement of lymph nodes.

Lymphoid interstitial pneumonia: a syndrome of fever, cough, and dyspnea owing to dense accumulations of lymphocytes at the alveolar interstitium.

Midline granulomatous disease: a disease characterized by necrotizing granulomas of the head and neck. It is most commonly caused by granulomatosis with polyangiitis disease, natural killer or T cell lymphomas, cocaine abuse, or infections.

Molecular mimicry: sequence similarities between foreign and self-peptides that allow for the development of cross-reactive T or B cells and autoimmunity.

Pancytopenia: reduction in the number of all blood cell subpopulations (red blood cells, white blood cells and platelets).

Plasmacytoid dendritic cells: one of the two principal subsets of human dendritic cells (DCs) with a plasma cell-like morphology.

Polyangiitis: inflammation involving multiple blood or lymph vessels.

Ribosomopathies: collection of disorders in which genetic abnormalities cause impaired ribosome biogenesis and function, such as Diamond–Blackfan anemia, Shwachman–Diamond syndrome, X-linked dyskeratosis congenita, cartilage hair hypoplasia, and Treacher Collins syndrome.

Sarcoid-like granulomas: granulomas that do not display necrosis and are surrounded by concentric scar tissue (fibrosis).

*Corresponding author*: Grammatikos, A.P. (agramma1@bidmc.harvard.edu).

Figure 1. **Immune system defects and autoimmunity.** The development of multiple subclinical infections may represent the triggering event in autoimmune patients that leads to uncontrolled immune system activation and chronic inflammation. A decline in immunity triggered by environmental factors (e.g. diet or psychological effectors) in combination with the presence of mild immune system defects may allow these infections to develop.

meningitidis, the causative agent of meningitis [8], Toll-like receptor 3 (TLR3)-deficient individuals, who are prone to herpes simplex virus (HSV) encephalitis [9], and MyD88-deficient patients, who are prone to invasive pneumococcal disease [10].

Immune defects in SLE

Primary immunodeficiency syndromes (PIDs) result from distinct defects of immune genes, whereas in SLE, besides rare cases such as *C1q* and *C4* deficiencies, widespread SNPs and gene variants appear to contribute subtly to aberrant immune system function [11]. Thus, weakly contributing genetic factors allow ample space for environmental influences (e.g. infections, diet or psychology) [12] and other factors to contribute to the manifestation of autoimmunity and related pathology (Figure 1).

SLE patients experience a high rate of infections, even from opportunistic pathogens normally observed in immunocompromised individuals, such as *Toxoplasma gondii*, *Pneumocystis carinii* and *Cryptococcus neoformans* [13]. There is increasing evidence that these infections, at both a clinical and subclinical level, may represent the primary trigger for constant immune system activation and autoimmunity (Figure 1) [14,15]. Infection causes neutrophils to form web-like structures, the so-called neutrophil extracellular traps (NETs) [16]. Increased formation of NETs has been reported in SLE, although this formation has not been linked to a specific infection [17,18]. Several pathways have been described that allow an immune response against a particular microbial agent to develop into generalized immune system activation and autoimmunity (Box 1).

In a genetically predisposed individual, exposure to environmental factors may be chronic and begin long

---

Box 1. Spread of inflammation and development of systemic autoimmunity

The higher number of infections that affect patients with SLE could contribute to the development of systemic inflammation. Epitope spreading, superantigen activation, and bystander activation are some of the mechanisms through which the spread of the inflammatory response can occur.

1. **Epitope spreading** Antigen-presenting cells (APCs) that recognize a viral epitope internalize the whole protein and not just the specific epitope, allowing them to present many different types of antigenic determinants to T cells [78]. In this way, multiple T-cell specificities can be generated from a single epitope, allowing for the subsequent activation of multiple B cell clones [79]. Under physiological conditions, epitope spreading is beneficial in that it allows for the generation of a rapid and robust immune response from a single antigenic determinant. However, it can also function in a harmful manner by leading to the generation of autoreactive cells. The fact that multiple antibody specificities accrue over time in SLE, so that the average number of autoantigens recognized gradually increases, suggests that epitope spreading might indeed occur early on in the course of this disease [80].

2. **Superantigen activation** Several bacterial pathogens, such as *Staphylococcus* and *Mycoplasma*, exhibit superantigen properties. Superantigens have the unique capacity to cross-link several T cell receptors, and thus activate many different antigenic specificities synchronously [81,82]. Again, not only are immune responses against pathogens enhanced by this process, but self-reactive clones can also be generated [83]. Evidence for the involvement of superantigens in the pathogenesis of two other autoimmune diseases, experimental autoimmune encephalomyelitis (EAE) and inflammatory bowel disease, has been produced.

3. **Bystander activation** Apart from engulfing microbial particles, APCs in the inflammatory microenvironment also take up apoptotic material from host cells that are present. Peptides from this material can then be presented to T cells and, in the context of inflammation, autoreactive T cell clones can be generated [84,85].

before disease development, as can be concluded from reports that autoantibodies appear several years prior to disease diagnosis [19]. Increased susceptibility to infection in patients with SLE [20] may very well exist before the development of clinical disease and during the long period of preexisting autoimmunity. Exposure to infections and other environmental factors occurs in a discontinuous fashion and may fuel the immune system, causing a disease flare [13,21].

Infections implicated in the pathogenesis of SLE

One characteristic of SLE is the 'interferon (IFN) signature', a significant upregulation of type I IFN-inducible genes (IFN-α and IFN-β) in peripheral blood cells [22], which suggests the presence of high levels of IFN-α and IFN-β cytokines (Box 2). The IFN signature seems to strongly support the idea that a chronic viral infection is involved in the pathogenesis of SLE. An immune system defect that allows uncontrolled viral proliferation and

reactive immune cell activation could underlie the high IFN production. Indeed, high numbers of infiltrating plasmacytoid dendritic cells (pDCs), one of the major producers of type I IFNs, are observed in skin and renal lesions from SLE patients [23,24]. Furthermore, pathogen-associated nucleic acids seem to be able to exacerbate SLE pathology [21]. Cultured mesangial cells that are exposed to synthetic polyinosinic–cytidylic acid (pI:C) RNA *in vitro* produce CCL2 as well as IL6, and *in vivo* injection of pI:C RNA increases serum IL-12p70, IL6, and IFN-α levels.

One candidate viral pathogen implicated in SLE immunopathogenesis is the Epstein–Barr virus (EBV). Infectious mononucleosis caused by EBV exhibits similar epidemiologic characteristics as SLE, in that they both afflict young adults, are less common in areas where primary EBV infection is endemic, and follow the same geographic latitude gradient [25]. Once infected, SLE patients seroconvert to EBV faster than controls and the EBV load is higher in SLE-affected individuals [26]. In a

---

Box 2. Type I interferon (IFN) production pathways

Plasmacytoid dendritic cells (pDCs) represent one of the major sources of IFN-α. These cells carry pattern-recognition receptors (PRRs) that are able to recognize evolutionarily conserved structures on infectious microorganisms as 'foreign' and trigger an immune system reaction against them (Figure I). Two different types of PRRs are involved in this process, TLRs (Toll-like receptors) and CNARs (cytosolic nucleic acid receptors).

Located in endosomal compartments, TLRs scan phagocytosed material for the presence of viral particles [86,87]. Single-strand RNA and double-strand DNA from viral particles are recognized by TLR7

and TLR9 receptors, respectively [87]. CNARs, by contrast, are present in all nucleated cells and allow recognition of viral particles directly at their point of entry. Examples of such receptors include RIG-I (retinoic acid-inducible gene I), MDA5 (melanoma differentiation-associated gene) and DAI (DNA-dependent activator of IFN-regulatory factors) [88]. When either of these two pathways is activated, the end result is the production of type I IFNs. Binding of IFNs to their respective receptors on infected cells allows the latter to activate intracellular pathways that limit pathogen replication and promote clearance.


TRENDS in Molecular Medicine

Figure I. Type I interferon production. Toll-like receptors (TLRs) in endosomal compartments and cytosolic nucleic acid receptors (CNARs) scan phagocytosed material for the presence of viral particles. Upon recognition of their respective ligands, type I interferons responsible for activating intracellular pathways that promote pathogen clearance are produced (IFN-α and IFN-β).

Table 1. Immunodeficiency and associated autoimmune diseases

Disease	Defective molecule (involved in)	Infectious manifestations	Autoimmune or lymphoproliferative manifestations	Refs
FHL	Perforin gene (T and NK cell cytotoxicity)	Increased viral infections	HLH (inflammation and tissue destruction)	[34]
XLP	SLAM-associated protein (SAP) (CD8+ T and NK cell signaling pathways)	Uncontrolled EBV infection	HLH (inflammation and tissue destruction), lymphoma	[29,30]
WAS	WAS protein (WASP) (actin cytoskeleton)	Recurrent bacterial infections	ITP, AHA, vasculitis, eczema, lymphoma	[67]
CGD	NADPH oxidase (neutrophil bactericidal mechanisms)	Recurrent bacterial and/or fungal infections	Chronic gut and/or lung inflammation	[64]
MGD	*RAG1*, *RAG2* (somatic rearrangement of Ig and TCR genes)	Systemic viral infections (CMV, EBV, VZV)	Caseating granulomas of the nose, sinuses, palate, and upper airways	[65,66]
APECED	*AIRE* gene (deletion of autoreactive lymphocyte clones)	Candidiasis	Organ-specific autoimmunity (parathyroid, adrenals)	[69]
CVID	*TACI, ICOS, BAFFR, CD19*, and *MSH5* genes (antibody production)	Recurrent sinopulmonary and GIT infections	IBD, ITP, AHA, LIP, lymphoma	[72,73]
IgAD	IgA antibody production	Recurrent infections	SLE, rheumatoid arthritis, ITP, allergy, asthma	[71,70]
XLA	Btk (B cell development and signaling)	Recurrent infections	Arthritis, AHA, scleroderma, type 1 diabetes	[74]

Abbreviations: FHL, familial hemophagocytic lymphohistiocytosis; HLH, hemophagocytic lymphohistiocytosis; XLP, X-linked lymphoproliferative syndrome; SLAM, signaling lymphocyte-activation molecule; EBV, Epstein–Barr virus; WAS, Wiskott–Aldrich syndrome; ITP, immune thrombocytopenia; CGD, chronic granulomatous disease; NADPH, nicotinamide adenine dinucleotide phosphate; MGD, midline granulomatous disease; RAG, recombination activating genes; Ig, immunoglobulin; TCR, T cell receptor; CMV, cytomegalovirus; VZV, varicella-zoster virus; APECED, autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy; AIRE, autoimmune regulator; CVID, common variable immunodeficiency; TACI, transmembrane activator and calcium-modulator and cyclophilin ligand interactor; ICOS, inducible T-cell costimulator; BAFFR, B cell-activating factor receptor; MSH5, MutS protein homolog 5; GIT, gastrointestinal tract; IBD, inflammatory bowel disease; AHA, autoimmune hemolytic anemia; LIP, lymphoid interstitial pneumonia; IgAD, IgA deficiency; XLA, X-linked agammaglobulinemia; Btk, Bruton's tyrosine kinase.

study performed in young adult lupus patients, 99% of them had antibodies against EBV antigens in peripheral blood, compared with only 70% of their matched controls [27]. It appears that SLE CD8+ T cells cannot effectively respond to EBV-infected B cells, as demonstrated by the fact that very low proportions of EBV-specific CD8+ T cells are able to produce IFN-γ in SLE patients in comparison with controls [28].

An association between EBV infection and autoimmunity has already been established for X-linked lymphoproliferative syndrome (XLP). XLP, a disease due to deficiency of the SLAM-associated protein (SAP), is characterized by chronic inflammatory responses and a hemophagocytic lymphohistiocytosis picture (Table 1) [29]. SAP is known to be part of signaling pathways in T cells and natural killer (NK) cells, and its absence seems to result in an inability to counteract acute EBV infection, which leads to the chronic inflammation observed in these patients [30].

An association between parvovirus B19 infection and SLE has also been reported. Parvovirus B19 DNA and IgM anti-B19 antibodies have been reported in a small groups of patients and it has been proposed that an undefined molecular mimicry is the linking mechanism [31].

Despite the presence of several lines of evidence suggesting the involvement of infectious agents in SLE immunopathogenesis, there are a number of reasons why distinct infectious agents causing SLE may never be found: (i) it is difficult to track individuals who are predisposed to develop SLE and observe the events they experience before becoming ill; (ii) the pathogenesis of SLE is probably the result of different factors acting together over time or simultaneously; (iii) more than one infectious agents may be involved; and (iv) the pathogen responsible may be an as yet unidentified infectious agent.

Defective immune response and pathogen clearance in SLE

SLE patients exhibit several immune defects that involve both the innate and adaptive immune pathways. In many cases, these affect proper pathogen recognition and/or clearance.

T cells and NK cells

CD8+ T cells, one of the most important players in antiviral immune defense, exhibit defective cytolytic abilities in patients with SLE, a defect that has not been found in any other autoimmune disease [32]. Lack of perforin leads not only to defective pathogen clearance but also to accelerated humoral autoimmunity and lupus-like disease in mice [33]. A similar situation has been reported in humans, where complete loss of perforin function presents as familial hemophagocytic lymphohistiocytosis (FHL), a fatal autoimmune disorder of early childhood [34]. CD8+ T cell responses against EBV, one of the potential candidates for SLE pathogenesis, are decreased in patients with SLE [35] and these patients have fewer IFN-γ-producing cells against influenza virus A H1N1 strain compared with control subjects [36].

CD4+ T helper cells also seem to be dysfunctional in SLE patients and exhibit an aberrant helper activity [37]. IL2 production from CD4+ T helper cells, required for the differentiation and survival of antigen-specific CD8+ T cells, is decreased in SLE patients [38]. Reduced CD4+ T cell responses against varicella zoster virus and a higher incidence of herpes zoster infection are also observed [39]. Furthermore, T helper cell responses against recall antigens are decreased in SLE patients. Both CD4+ and CD8+ T cells display increased rates of spontaneous apoptosis in SLE patients [40], leading to decreased cell numbers and a decreased immune defense repertoire.

The decreased CD3ζ chain expression observed in SLE patients could explain some of the above findings [1,2]. The CD3ζ chain constitutes part of the T-cell receptor (TCR) signaling machinery and is responsible for transmitting downstream signals upon antigen recognition. Lack of CD3ζ expression could contribute to the defective immune responses against infections observed in SLE. Consistent with this, defective TCR signaling has been shown to lead to the development of a lethal, multiorgan autoimmune disease in mice [41]. Mutations in the gene encoding for ZAP70, a downstream signaling target of the CD3ζ complex, also lead to the development of autoimmunity in mice [42]. Infectious agents seem to play an important role because mice bred in a microbial-free environment do not develop autoimmunity [43].

Finally, the number of NK cells, another key player in the defense against viral infections, is also decreased in SLE patients [44]. Overall, these defects suggest inadequate antiviral immunity in SLE patients. This could be responsible for the spread of multiple viral infections, both at a clinical and a subclinical level.

Complement

Complement deficiencies, a distinct group of immunodeficiencies, provide a perfect background for the development of both autoimmunity and infections. Early complement component deficiency frequently leads to the development of autoimmunity and autoimmune-like manifestations (93% of individuals with C1q deficiency, 60–66% of individuals with C1 s or C1r deficiency, 90% of individuals with C4 deficiency and 10% of individuals with C2 deficiency) [45]. Lack of C1 inhibitor, responsible for the development of angioedema, has been linked in some cases to lupus nephritis and other autoimmune manifestations [46]. Late complement factor deficiencies, by contrast, are linked preferentially to infections and not to autoimmunity [47].

Decreased expression of complement receptor 1 (CR1), the complement receptor for C3B, on erythrocytes, polymorphonuclear cells and B cells in SLE patients may account for the defective phagocytic capacity toward infectious microorganisms [48]. This is probably accentuated in certain patients who carry the R77H allele of *ITGAM* (which encodes Mac-1, also known as CR3). One of the Mac-1 ligands is C3bi, and therefore, complement-dependent opsonization and phagocytosis are compromised in these patients [49].

Decreased mannose-binding lectin (MBL) is the most common immunodeficiency in humans, with 5% of the population affected. Although the phenotype of this deficiency is usually mild, an increased prevalence of SLE has been reported in these patients [50]. Similar to the case of early complement components of the classical pathway, both rheumatic manifestations and higher rates of infections are observed in patients suffering from MBL deficiency.

MHC-I and ribosomal genes

Microarray studies performed in SLE patients have revealed that major histocompatibility complex class I (MHC-I) and ribosomal-related genes are underexpressed compared with controls [51]. Conversely, patients with MHC-I deficiency (bare lymphocyte syndrome) sometimes exhibit autoimmune phenomena reminiscent of granulomatosis with polyangiitis [52]. Lupus-prone mice with β2 microglobulin deficiency (a component of MHC-I) exhibit accelerated skin disease [53]. MHC-I is required for the detection of intracellular pathogens by CD8[+] T cells, and its absence seems to lead to a failure to defend against such pathogens. A certain gene transcription signature in CD8[+] T cells has been linked to SLE disease prognosis [54].

Similarly, patients with ribosomopathies commonly present features of immune deficiency [55]. Ribosomopathies are a diverse collection of genetic disorders leading to bone marrow failure, typical examples of which are Diamond–Blackfan anemia (DBA) and Shwachman–Diamond syndrome (SDS). Several immune defects have been described in these patients, including low numbers and reduced function of both T cells and B cells. Low expression levels of ribosome-related genes in SLE patients could have similar effects on the immune system, making the clearance of pathogens less effective.

B cells

B cells from patients with SLE are characteristically polyclonally activated and produce autoantibodies against a large array of self-antigens [1]. Lower numbers of naïve B cells and higher numbers of antibody-producing plasma cells are routinely recorded [56].

Certain autoantibodies have been linked to pathology, yet IgM autoantibodies may have a protective role [57]. The fact that lupus-prone mice that lack soluble antibodies still develop lupus-like disease supports the idea that SLE pathology may occur independently of soluble autoantibodies [58]. Indeed, instead of hypergammaglobulinemia, decreased immunoglobulin levels or even typical combined variable immunodeficiency (CVID) [59,60] is observed in some SLE patients. As many as 6% of SLE patients display concurrent IgA deficiency, and the same drugs that have been associated with this have also been associated with the development of SLE (e.g. phenytoin, D-penicillamine and sulfasalazine) [61].

Other cell types

Both monocytes and macrophages from SLE patients exhibit increased levels of apoptosis. Furthermore, monocytes exhibit decreased levels of FcRII and FcRIII receptors on their surface membrane in SLE patients, and both are necessary for the phagocytosis of foreign and apoptotic material [62]. Monocyte-derived DCs from patients with SLE also exhibit diminished phagocytic capacity associated with decreased expression of specific C-type lectin receptors on their surface [63].

Autoimmune manifestations in immunodeficiency diseases

Clinical and laboratory findings consistent with autoimmunity are common in immunodeficient patients (Table 1). The decreased ability of the immune system to clear infections in these patients can cause perpetual immune-system activation and autoimmunity.

Familial hemophagocytic lymphohistiocytosis (FHL) is an autosomal recessive PID in which a defect in

perforin excretion has been documented [34]. Lack of perforin deprives the immune system of one of its main effectors against viral infections. In response to multiple uncleared viral infections, an overwhelming activation of T lymphocytes and macrophages as well as persistent inflammatory responses are seen in these patients. As a consequence, multiple autoimmune phenomena develop, including pancytopenia, rashes, lymphadenopathy and hepatosplenomegaly.

In chronic granulomatous disease, where there is decreased production of NADPH oxidase by neutrophils, recurrent bacterial and fungal infections develop, followed by chronic inflammation of the gut and lungs. Furthermore, asymptomatic carriers of the defective genes are reported to have an increased incidence of discoid lupus [64].

Defects in recombinase activation genes (*RAG*) have been associated with severe combined immunodeficiency syndromes (SCID), yet a recent study reported hypomorphic *RAG* mutations (resulting in 50% RAG activity) in patients suffering from midline granulomatous disease [65]. Midline granulomatous disease is an autoimmune disorder commonly observed in patients with granulomatosis with polyangiitis and NK or T cell lymphomas. In this case also, although the complete absence of the gene product seems to be associated with profound immunodeficiency, autoimmune phenomena prevail in partial deletion [66].

Patients with Wiskott–Aldrich syndrome (WAS) lack the WAS protein (WASP), which is involved in regulation of the actin cytoskeleton. Affected individuals present with eczema, autoimmune manifestations, recurrent bacterial infections and lymphoma [67]. Both antibody production and cellular immune defects are observed in these patients and predispose individuals to chronic inflammation. Interestingly, malignancy develops primarily in patients with autoimmune manifestations [68].

Autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) is another example in which autoimmunity and infections coexist. Although generally considered a disease of immune regulation dysfunction with organ-specific autoimmune manifestations (e.g. hypoparathyroidism and adrenocortical failure), chronic mucocutaneous candidiasis is also invariably present [69]. Although current concepts support the existence of regulatory pathway defects in this disease, a plausible explanation for the fact that infections are also commonly observed in these patients is still missing.

IgA deficiency is the most common type of primary immunodeficiency and although it can exist undiagnosed, it is associated with the development of autoimmune and atopic phenomena in a substantial number of patients. Unaffected relatives of IgA-deficient patients also have a higher prevalence for autoimmune manifestations compared with the general population [70]. What is even more interesting is that IgA deficiency is frequently found in patients previously diagnosed with autoimmune diseases such as SLE (1–5.2%) and rheumatoid arthritis (2–4.7%) [71].

CVID patients display low IgG and IgM levels and decreased antibody responses to common infectious agents [72]. Autoimmune diseases such as inflammatory bowel disease (IBD), autoimmune thrombocytopenia and thyroid disease are frequently present [73], and lymphoproliferative diseases, including lymphoid interstitial pneumonia, sarcoid-like granulomas and even lymphoma, are frequently observed.

In X-linked agammaglobulinemia (XLA) patients, identified by low or absent B cells and low immunoglobulin levels, many autoimmune diseases are present, including arthritis, autoimmune hemolytic anemia, scleroderma and type 1 diabetes mellitus (T1DM), in addition to chronic and/or recurrent infections [74].

Concluding remarks

Emerging information on the genetic basis of various diseases has facilitated a better appreciation of the diverse effects that genetic susceptibility defects can have on clinical disease phenotypes. In particular, recent findings on SLE immunopathogenesis have allowed us to better appreciate the association between autoimmune manifestations and subtle immune system defects. Such immune defects, by virtue of not being critical enough to allow overwhelming infections to develop, seem to provide the perfect background for chronic inflammatory responses. Although no single pathogen has yet been associated with SLE immunopathogenesis, recent data seem to converge towards the fact that chronic inflammation in SLE could stem from the presence of chronic immune system activation towards an uncleared intruder.

Apart from SLE, it seems that this link may also apply to other autoimmune diseases such as T1DM, multiple sclerosis (MS), rheumatoid arthritis (RA), IBD and Sjögren's syndrome. Genetic studies have confirmed that polymorphisms within an interferon inducible gene, *IRF5*, are linked to a predisposition to not only SLE, but also MS, RA, IBD and Sjögren's syndrome [72]. T1DM has also been linked to an IFN signature similar to the one observed in SLE, and polymorphisms of *MDA5* (a gene encoding a cytosolic nucleic acid receptor) are associated with predisposition to T1DM in genome-wide association studies [75,76]. Finally, high numbers of EBV-infected B cells are observed in tertiary lymphoid tissues of the central nervous system in MS patients [77]. Thus, it seems that different autoimmune diseases might share common molecular defects and could share the same pattern of immunodeficiency that leads to the chronic infection and immune hyper-reactivity proposed above.

We have presented information that suggests overlapping features between systemic autoimmunity and immunodeficiency. Patients with SLE develop infections because of defects in elements of the immune response. Similarly, patients with immunodeficiency present with autoimmune manifestations. In states of immunodeficiency, defects in immune response genes lead to uncleared infections and autoimmunity, whereas in systemic autoimmunity, subtle defects of immune response genes lead both directly to autoimmunity and indirectly by failure to clear pathogens, whose presence amplifies the autoimmune process (Figure 2). Although autoimmunity and immunodeficiency occupy distinct chapters in textbooks, it appears that they are inextricably interconnected and

Figure 2. **Scale of the severity of immune system-related genetic defects**. Milder genetic defects may result in multiple subclinical infections and the development of an autoimmunity-based phenotype. More severe genetic defects may manifest as the presence of frequent and/or severe infections and a more immunodeficiency-oriented phenotype.

one should be always considered in the presence of the other.

Disclosure statement
The authors have no conflicts of interest.

References
1 Tsokos, G.C. (2011) Systemic lupus erythematosus. *N. Engl. J. Med.* 365, 2110–2121
2 Crispin, J.C. *et al.* (2010) Pathogenesis of human systemic lupus erythematosus: recent advances. *Trends Mol. Med.* 16, 47–57
3 Cunninghame Graham, D.S. (2009) Genome-wide association studies in systemic lupus erythematosus: a perspective. *Arthritis Res. Ther.* 11, 119
4 Sellam, J. *et al.* (2007) Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. *Ann. Rheum. Dis.* 66, 790–797
5 Warnatz, K. *et al.* (2009) B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. *Proc. Natl. Acad. Sci. U.S.A.* 106, 13945–13950
6 Alcais, A. *et al.* (2009) Human genetics of infectious diseases: between proof of principle and paradigm. *J. Clin. Invest.* 119, 2506–2514
7 Grammatikos, A.P. (2008) The genetic and environmental basis of atopic diseases. *Ann. Med.* 40, 482–495
8 Tsokos, G.C. and Fleming, S.D. (2004) Autoimmunity, complement activation, tissue injury and reciprocal effects. *Curr. Dir. Autoimmun.* 7, 149–164
9 Zhang, S.Y. *et al.* (2007) TLR3 deficiency in patients with herpes simplex encephalitis. *Science* 317, 1522–1527
10 von Bernuth, H. *et al.* (2008) Pyogenic bacterial infections in humans with MyD88 deficiency. *Science* 321, 691–696
11 Moser, K.L. *et al.* (2009) Recent insights into the genetic basis of systemic lupus erythematosus. *Genes Immun.* 10, 373–379
12 Hewagama, A. and Richardson, B. (2009) The genetics and epigenetics of autoimmune diseases. *J. Autoimmun.* 33, 3–11
13 Doria, A. *et al.* (2008) Infections as triggers and complications of systemic lupus erythematosus. *Autoimmun. Rev.* 8, 24–28
14 Deng, G.M. and Tsokos, G.C. (2008) Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. *J. Immunol.* 181, 4019–4026
15 Poole, B.D. *et al.* (2009) Aberrant Epstein–Barr viral infection in systemic lupus erythematosus. *Autoimmun. Rev.* 8, 337–342
16 Hakkim, A. *et al.* (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. *Proc. Natl. Acad. Sci. U.S.A.* 107, 9813–9818
17 Villanueva, E. *et al.* (2011) Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. *J. Immunol.* 187, 538–552
18 Garcia-Romo, G.S. *et al.* (2011) Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. *Sci. Transl. Med.* 3, 73ra20
19 Heinlen, L.D. *et al.* (2007) Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. *Arthritis Rheum.* 56, 2344–2351

20 Iliopoulos, A.G. and Tsokos, G.C. (1996) Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. *Semin. Arthritis Rheum.* 25, 318–336
21 Patole, P.S. *et al.* (2005) Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. *J. Am. Soc. Nephrol.* 16, 1326–1338
22 Feng, X. *et al.* (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. *Arthritis Rheum.* 54, 2951–2962
23 Tucci, M. *et al.* (2008) Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. *Arthritis Rheum.* 58, 251–262
24 Farkas, L. *et al.* (2001) Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. *Am. J. Pathol.* 159, 237–243
25 Crawford, D.H. *et al.* (2002) Sexual history and Epstein–Barr virus infection. *J. Infect. Dis.* 186, 731–736
26 Gross, A.J. *et al.* (2005) EBV and systemic lupus erythematosus: a new perspective. *J. Immunol.* 174, 6599–6607
27 James, J.A. *et al.* (1997) An increased prevalence of Epstein–Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. *J. Clin. Invest.* 100, 3019–3026
28 Berner, B.R. *et al.* (2005) Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. *Cell Immunol.* 235, 29–38
29 Rezaei, N. *et al.* (2011) X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. *Br. J. Haematol.* 152, 13–30
30 Detre, C. *et al.* (2010) SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. *Semin. Immunopathol.* 32, 157–171
31 Aslanidis, S. *et al.* (2008) Parvovirus B19 infection and systemic lupus erythematosus: activation of an aberrant pathway? *Eur. J. Intern. Med.* 19, 314–318
32 Puliaeva, I. *et al.* (2009) Therapeutic potential of CD8$^+$ cytotoxic T lymphocytes in SLE. *Autoimmun. Rev.* 8, 219–223
33 Peng, S.L. *et al.* (1998) Perforin protects against autoimmunity in lupus-prone mice. *J. Immunol.* 160, 652–660
34 Herman, T.E. and Siegel, M.J. (2010) Familial hemophagocytic lymphohistiocytosis. *J. Perinatol.* 30, 363–365
35 Kang, I. *et al.* (2004) Defective control of latent Epstein–Barr virus infection in systemic lupus erythematosus. *J. Immunol.* 172, 1287–1294
36 Holvast, A. *et al.* (2009) Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. *Arthritis Rheum.* 60, 2438–2447
37 Crispin, J.C. *et al.* (2008) How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. *Trends Immunol.* 29, 110–115
38 Lieberman, L.A. and Tsokos, G.C. (2010) The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. *J. Biomed. Biotechnol.* 2010, 740619
39 Park, H.B. *et al.* (2004) Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. *J. Rheumatol.* 31, 2151–2155
40 Dhir, V. *et al.* (2009) Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study. *Lupus* 18, 785–791
41 Holst, J. *et al.* (2008) Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. *Nat. Immunol.* 9, 658–666
42 Cope, A.P. (2004) Altered signalling thresholds in T lymphocytes cause autoimmune arthritis. *Arthritis Res. Ther.* 6, 112–116
43 Yoshitomi, H. *et al.* (2005) A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. *J. Exp. Med.* 201, 949–960
44 Huang, Z. *et al.* (2011) Involvement of CD226$^+$ NK cells in immunopathogenesis of systemic lupus erythematosus. *J. Immunol.* 186, 3421–3431
45 Arason, G.J. *et al.* (2010) Primary immunodeficiency and autoimmunity: lessons from human diseases. *Scand. J. Immunol.* 71, 317–328
46 Ochonisky, S. *et al.* (1993) Acquired C1 inhibitor deficiency revealing systemic lupus erythematosus. *Dermatology* 186, 261–263
47 Chen, M. *et al.* (2010) The complement system in systemic autoimmune disease. *J. Autoimmun.* 34, J276–J286

48 Isaak, A. *et al.* (2008) Physiological up-regulation of inhibitory receptors Fc gamma RII and CR1 on memory B cells is lacking in SLE patients. *Int. Immunol.* 20, 185–192

49 Deng, Y. and Tsao, B.P. (2010) Genetic susceptibility to systemic lupus erythematosus in the genomic era. *Nat. Rev. Rheumatol.* 6, 683–692

50 Dommett, R.M. *et al.* (2006) Mannose-binding lectin in innate immunity: past, present and future. *Tissue Antigens* 68, 193–209

51 Chaussabel, D. *et al.* (2008) A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. *Immunity* 29, 150–164

52 Villa-Forte, A. *et al.* (2008) HLA class I deficiency syndrome mimicking Wegener's granulomatosis. *Arthritis Rheum.* 58, 2579–2582

53 Chan, O.T. *et al.* (2001) Deficiency in beta$_2$-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas^{lpr} mice: an example of disease regulation at the organ level. *J. Immunol.* 167, 2985–2990

54 McKinney, E.F. *et al.* (2010) A CD8$^+$ T cell transcription signature predicts prognosis in autoimmune disease. *Nat. Med.* 16, 586–591

55 Khan, S. *et al.* (2011) Do ribosomopathies explain some cases of common variable immunodeficiency? *Clin. Exp. Immunol.* 163, 96–103

56 Odendahl, M. *et al.* (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. *J. Immunol.* 165, 5970–5979

57 Kuan, A.P. *et al.* (2000) Immunoglobulin isotype determines pathogenicity in antibody-mediated myocarditis in naive mice. *Circ. Res.* 86, 281–285

58 Chan, O.T. *et al.* (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. *J. Exp. Med.* 189, 1639–1648

59 Torres-Salido, M. *et al.* (2011) Systemic lupus erythematosus as a first presentation of common variable immunodeficiency associated with infrequent mannose-binding lectin gene polymorphisms. *Rheumatol. Int.* 31, 537–541

60 Yong, P.F. *et al.* (2008) Management of hypogammaglobulinaemia occurring in patients with systemic lupus erythematosus. *Rheumatology (Oxford)* 47, 1400–1405

61 Skare, T.L. *et al.* (2010) Serum IgA deficiency in systemic lupus erythematosus. *Acta Reumatol. Port.* 35, 273–274

62 Katsiari, C.G. *et al.* (2010) The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. *Semin. Arthritis Rheum.* 39, 491–503

63 Monrad, S.U. *et al.* (2008) Myeloid dendritic cells display downregulation of C-type lectin receptors and aberrant lectin uptake in systemic lupus erythematosus. *Arthritis Res. Ther.* 10, R114

64 Holland, S.M. (2010) Chronic granulomatous disease. *Clin. Rev. Allergy Immunol.* 38, 3–10

65 De Ravin, S.S. *et al.* (2010) Hypomorphic Rag mutations can cause destructive midline granulomatous disease. *Blood* 116, 1263–1271

66 Walter, J.E. *et al.* (2010) Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. *J. Exp. Med.* 207, 1541–1554

67 Notarangelo, L.D. *et al.* (2008) Wiskott–Aldrich syndrome. *Curr. Opin. Hematol.* 15, 30–36

68 Sullivan, K.E. *et al.* (1994) A multiinstitutional survey of the Wiskott–Aldrich syndrome. *J. Pediatr.* 125, 876–885

69 Lankisch, T.O. *et al.* (2009) The autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy or autoimmune polyglandular syndrome type 1. *Semin. Liver Dis.* 29, 307–314

70 Jorgensen, G.H. *et al.* (2009) Familial aggregation of IgAD and autoimmunity. *Clin. Immunol.* 131, 233–239

71 Jacob, C.M. *et al.* (2008) Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper. *J. Clin. Immunol.* 28 (Suppl. 1), S56–S61

72 Bonilla, F.A. and Geha, R.S. (2009) Common variable immunodeficiency. *Pediatr. Res.* 65, 13R–19R

73 Cunningham-Rundles, C. and Bodian, C. (1999) Common variable immunodeficiency: clinical and immunological features of 248 patients. *Clin. Immunol.* 92, 34–48

74 Howard, V. *et al.* (2006) The health status and quality of life of adults with X-linked agammaglobulinemia. *Clin. Immunol.* 118, 201–208

75 Concannon, P. *et al.* (2008) A human type 1 diabetes susceptibility locus maps to chromosome 21q22.3. *Diabetes* 57, 2858–2861

76 Nejentsev, S. *et al.* (2009) Rare variants of *IFIH1*, a gene implicated in antiviral responses, protect against type 1 diabetes. *Science* 324, 387–389

77 Serafini, B. *et al.* (2007) Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. *J. Exp. Med.* 204, 2899–2912

78 Poole, B.D. *et al.* (2006) Epstein–Barr virus and molecular mimicry in systemic lupus erythematosus. *Autoimmunity* 39, 63–70

79 Vanderlugt, C.L. and Miller, S.D. (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. *Nat. Rev. Immunol.* 2, 85–95

80 Arbuckle, M.R. *et al.* (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N. Engl. J. Med.* 349, 1526–1533

81 Munz, C. *et al.* (2009) Antiviral immune responses: triggers of or triggered by autoimmunity? *Nat. Rev. Immunol.* 9, 246–258

82 Stow, N.W. *et al.* (2010) Superantigens. *Otolaryngol. Clin. North Am.* 43, 489–502

83 Wucherpfennig, K.W. (2001) Mechanisms for the induction of autoimmunity by infectious agents. *J. Clin. Invest* 108, 1097–1104

84 Zipris, D. *et al.* (2005) TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. *J. Immunol.* 174, 131–142

85 Boyman, O. (2010) Bystander activation of CD4$^+$ T cells. *Eur. J. Immunol.* 40, 936–939

86 Stetson, D.B. (2009) Connections between antiviral defense and autoimmunity. *Curr. Opin. Immunol.* 21, 244–250

87 Kawai, T. and Akira, S. (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. *Immunity* 34, 637–650

88 Wilkins, C. and Gale, M., Jr (2010) Recognition of viruses by cytoplasmic sensors. *Curr. Opin. Immunol.* 22, 41–47